Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $32.0500 (-5.51%) ($31.7800 - $34.5700) on Mon. Jan. 14, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8% (three month average) | RSI | 62 | Latest Price | $32.0500(-5.51%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -1.4% a day on average for past five trading days. | Weekly Trend | AUTL advances 6.2% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) DRIV(14%) IBB(14%) IWC(13%) EWI(12%) IWM(12%) | Factors Impacting AUTL price | AUTL will decline at least -4% in a week (0% probabilities). VXX(-7%) VIXM(-6%) TLT(-6%) DIA(-5%) BWX(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -4% (StdDev 8%) | Hourly BBV | 0 () | Intraday Trend | -2.7% | | | |
|
Resistance Level | $32.11 | 5 Day Moving Average | $33.77(-5.09%) | 10 Day Moving Average | $33.84(-5.29%) | 20 Day Moving Average | $32.11(-0.19%) | To recent high | -33.2% | To recent low | 28.8% | Market Cap | $1.675b | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |